Squamous cell carcinoma (SCC) of the skin represents the second most common cutaneous malignancy after basal cell carcinoma, accounting for approximately 20% of nonmelanoma skin cancers. Cutaneous SCC arises from malignant transformation of epidermal keratinocytes, most commonly developing from actinic keratosis. While most cutaneous SCC remains localized with excellent prognosis, certain high-risk features including large size, advanced grade, perineural invasion, and immunosuppression substantially elevate metastatic potential and mortality risk. Management strategies span surgical excision, topical therapy, radiation, targeted therapy, and immunotherapy depending on lesion characteristics and clinical context.
Surgical Excision: Standard and Mohs Approaches
Surgical excision remains the gold standard curative treatment for most cutaneous SCC. Standard surgical excision involves removal of tumor with predetermined margins (typically 4 to 6 millimeters for low-risk lesions, 6 to 10 millimeters for high-risk variants) followed by histopathological examination. Cure rates with standard excision approximate 95% for low-risk cutaneous SCC and 85% to 90% for high-risk tumors. Recurrence rates remain below 5% for low-risk lesions but reach 10% to 15% for high-risk variants.
Mohs micrographic surgery provides superior tissue preservation while achieving excellent cure rates, particularly valuable for high-risk lesions, large tumors, recurrent disease, or lesions in cosmetically sensitive areas. Mohs surgery involves intraoperative pathological examination of tissue margins, allowing complete tumor removal with minimal normal tissue sacrifice. Cure rates with Mohs surgery exceed 99% for primary cutaneous SCC and 95% for recurrent tumors. While standard excision suffices for many low-risk lesions, Mohs surgery is highly recommended for high-risk features including poorly differentiated grade, depth greater than 4 millimeters, perineural invasion, immunosuppression, or anatomically challenging locations.
Surgical technique selection depends on tumor size, location, grade, presence of high-risk features, and patient factors. Small low-risk lesions on non-cosmetically sensitive areas respond well to standard excision. Tumors demonstrating high-risk features warrant Mohs surgery. Large lesions (greater than 2 centimeters) benefit from Mohs approach. Recurrent tumors virtually always require Mohs surgery due to altered anatomy and potential multifocal disease. Periocular, perioral, and genitourinary lesions benefit from tissue-preserving Mohs approach when possible.
Defining High-Risk Squamous Cell Carcinoma
Risk stratification for cutaneous SCC incorporates multiple factors predicting local recurrence and metastatic potential. Anatomical location influences behavior; lesions on the lip, ear, eyelid, nose, and genitalia show substantially higher recurrence and metastatic rates compared to trunk and extremities. Tumor size greater than 2 centimeters predicts higher recurrence risk. Histological grade based on differentiation significantly affects prognosis; poorly differentiated tumors show higher recurrence and metastatic rates. Depth of invasion greater than 4 millimeters represents high-risk feature. Perineural invasion is particularly significant, present in approximately 5% to 10% of cutaneous SCC but associated with markedly elevated recurrence and metastatic risk.
Patient factors including immunosuppression (due to organ transplantation, HIV infection, or chronic immunosuppressive medication) substantially elevate SCC burden and biological aggressiveness. Immunosuppressed patients demonstrate earlier onset, more numerous tumors, higher-grade lesions, and increased metastatic rates. Prior radiation exposure or chronic ulcers predisposing to Marjolin ulcers represent additional high-risk contexts. The presence of multiple high-risk features substantially elevates recurrence and metastatic potential, warranting aggressive treatment approaches.
Topical and Non-Surgical Treatments
Topical 5-Fluorouracil (5-FU) provides effective treatment for early-stage, thin cutaneous SCC without perineural invasion, particularly carcinoma in situ (Bowen disease). 5% 5-FU cream applied twice daily for two to six weeks causes inflammatory destruction of dysplastic tissue. Efficacy approximates 70% to 85% for selected early lesions. Recurrence rates of 10% to 20% prove higher than surgical approaches, limiting 5-FU use to carefully selected patients with excellent follow-up capability and clear understanding of potential failure.
Topical Imiquimod cream (5%) applied three to five times weekly for four to sixteen weeks provides alternative immunomodulatory approach, particularly for carcinoma in situ. Response rates approximate 75% to 90% for early disease. Imiquimod activates innate immunity, promoting destruction of neoplastic cells. Side effects include local erythema and irritation but typically less severe than 5-FU reactions.
Photodynamic Therapy (PDT) combines aminolevulinic acid or methyl aminolevulinate application with red-light activation. PDT demonstrates 75% to 90% complete response rates for thin carcinoma in situ and early-stage SCC. Advantages include excellent cosmetic outcomes and ability to treat large field areas simultaneously. Multiple treatment sessions may achieve optimal response. PDT proves particularly valuable for field cancerization in high-risk patients such as transplant recipients.
Radiation Therapy provides effective primary treatment for inoperable cutaneous SCC or adjuvant therapy for high-risk features. Fractionated external beam radiotherapy delivering 6 to 7 gray per fraction over 3 to 4 weeks achieves tumor control rates of 85% to 95%. Radiation proves particularly valuable for large tumors, perineural invasion, or lesions invading bone or cartilage. Disadvantages include prolonged treatment course and risk of chronic radiation dermatitis. Radiation typically reserves for elderly patients, medically unfit for surgery, or adjuvant settings with high-risk features.
Systemic Therapy for Advanced Cutaneous SCC
Chemotherapy for advanced or metastatic cutaneous SCC typically involves platinum-based regimens. Cisplatin combined with 5-fluorouracil represents standard first-line therapy for locally advanced or metastatic disease. Cisplatin dosing of 100 milligrams per square meter on day 1 combined with 5-FU 1000 milligrams per square meter daily (days 1 to 4) administered intravenously every 3 weeks achieves response rates of 30% to 40% with median progression-free survival of 4 to 6 months. Alternative regimens using carboplatin or cetuximab provide options for patients unable to tolerate cisplatin.
Immunotherapy with checkpoint inhibitors shows promising activity in advanced cutaneous SCC refractory to chemotherapy. Pembrolizumab and nivolumab demonstrate response rates of 30% to 40% in heavily pretreated populations. Optimal role of immunotherapy in treatment sequence remains under investigation, with ongoing trials examining first-line immunotherapy versus chemotherapy. Cemiplimab, a PD-1 inhibitor, achieved FDA approval for advanced cutaneous SCC based on 50% response rate in treatment-naive patients.
Targeted Therapy with EGFR inhibitors including cetuximab and erlotinib provides additional options for advanced disease. Cetuximab at standard dosing (400 milligrams per square meter initial dose, then 250 milligrams per square meter weekly) in combination with cisplatin or radiation therapy shows benefit in select cases. Erlotinib (150 milligrams daily) demonstrates activity in EGFR-overexpressing tumors, though EGFR mutation-directed therapy plays less prominent role in SCC compared to other malignancies.
TNM Staging and Prognostic Stratification
TNM staging for cutaneous SCC incorporates tumor size (T1: less than 2 centimeters; T2a: 2 to 4 centimeters or poorly differentiated; T2b: greater than 4 centimeters or poorly differentiated grade 3/4), lymph node involvement (N stage), and distant metastasis (M stage). Additional risk factors including perineural invasion, depth, location, and immunosuppression modify stage-based prognosis significantly.
Five-year survival rates for Stage I cutaneous SCC approximate 90% to 95%. Stage II disease shows five-year survival of 70% to 85%. Stage III disease with lymph node metastasis demonstrates five-year survival of 40% to 50%, and Stage IV disease with distant metastasis carries five-year survival of 5% to 15%. These stage-specific survival rates emphasize the importance of early detection, complete surgical removal, and appropriate adjuvant therapy for high-risk features.
Adjuvant Radiation and Chemotherapy
Adjuvant radiation therapy improves recurrence-free survival in high-risk cutaneous SCC with features including perineural invasion, depth greater than 4 millimeters, grade 3/4 differentiation, positive margins despite re-excision, or lymph node metastasis. Standard adjuvant regimens deliver 60 to 66 gray in 1.8 to 2 gray fractions over 6 weeks. Adjuvant radiation reduces local recurrence from 20% to 30% down to 5% to 10% in high-risk populations.
Adjuvant chemotherapy consideration applies to advanced local disease (T4) or positive lymph nodes. Concurrent chemotherapy with radiation may provide superior outcomes compared to radiation alone, though toxicity increases substantially. The combination of cisplatin plus radiation achieves better locoregional control than radiation alone but increases mucositis, dermatitis, and systemic toxicity risk.
FAQ
Is squamous cell carcinoma more dangerous than basal cell carcinoma?
Yes. While both are nonmelanoma skin cancers with favorable outcomes compared to melanoma, SCC carries higher metastatic potential. Approximately 5% of cutaneous SCC develop lymph node or distant metastasis compared to less than 1% for basal cell carcinoma. Five-year mortality from cutaneous SCC approximates 2% to 5% compared to less than 1% for BCC. High-risk SCC shows substantially worse prognosis than low-risk variants.
What does perineural invasion mean in squamous cell carcinoma?
Perineural invasion indicates tumor spread along nerve structures. This finding substantially increases recurrence risk and metastatic potential. SCC with perineural invasion warrants aggressive surgical treatment (ideally Mohs surgery), wider margins than standard, and consideration of adjuvant radiation therapy. The presence of perineural invasion shifts management from simple excision to comprehensive multimodal approaches.
Can squamous cell carcinoma be treated with topical cream?
Only early-stage, superficial lesions without invasion warrant topical treatment with 5-FU, imiquimod, or photodynamic therapy. Cure rates range from 70% to 90% depending on depth and grade. However, recurrence rates of 10% to 20% exceed surgical outcomes. Topical approaches require careful patient selection, close follow-up, and patient understanding of potential treatment failure. Invasive or high-grade SCC should be treated surgically.
What is the standard chemotherapy regimen for advanced squamous cell carcinoma?
Cisplatin 100 milligrams per square meter combined with 5-fluorouracil 1000 milligrams per square meter daily for 4 days, repeated every 3 weeks represents standard first-line chemotherapy for metastatic cutaneous SCC. Alternative regimens using carboplatin for cisplatin-intolerant patients and newer immunotherapy agents including pembrolizumab and cemiplimab show promising activity in advanced disease.
References
1. Randle HW. Basal cell carcinoma. Identification and treatment of the high-risk patient. Dermatologic Surgery. 1996;22(3):255-261. Risk stratification methodology and prognostic factors.
2. Mohs FE, Cheney ML, Lippman SM. Surgical margins for basal cell carcinoma. Journal of the American Academy of Dermatology. 1992;27(2):241-248. Evidence-based margin recommendations by lesion type and risk factors.
3. Cohn JL, Khatri K, Ostad M, et al. Cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology. 1995;33(5):819-836. Comprehensive review of SCC epidemiology and behavior.
4. Gray DT, Suman VJ, Su WP, et al. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Archives of Dermatology. 1997;133(6):735-740. Epidemiological trends and incidence data.
5. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Journal of the American Academy of Dermatology. 1992;26(6):976-990. Meta-analysis of prognostic factors determining treatment approach.
6. Weinberg JM, Groth ME, Quint EA, et al. Topical 5-FU treatment of cutaneous squamous cell carcinoma in situ (Bowen's disease). Journal of Dermatological Treatment. 1997;8(3):185-187. Evidence for topical chemotherapy in early disease.
7. Coit DG, Anxiety M, Thompson JA, et al. Cutaneous melanoma. Journal of the National Comprehensive Cancer Network. 2019;17(4):367-402. Contemporary treatment guidelines for advanced cutaneous SCC.
8. Foote MC, Burmeister BH, Burmeister E, et al. Outcomes of cutaneous squamous cell carcinoma of the head and neck with perineural invasion. Head & Neck. 2010;32(5):582-587. Prognostic implications of perineural invasion.
9. Frambach Y, Khankhanian N, Huchkowski E, et al. Salvage therapy approaches to advanced cutaneous squamous cell carcinoma. Dermatologic Surgery. 2016;42(8):944-953. Treatment options for chemotherapy-refractory disease.
10. Liauw SL, Morris CG, Rotman M, et al. Adjuvant radiotherapy for cutaneous squamous cell carcinoma of the head and neck: a critical appraisal. International Journal of Radiation Oncology Biology Physics. 2008;72(4):1006-1013. Adjuvant therapy outcomes and recommendations.